Sulfadiazine Suspension

This product belongs to the sulfonamide broad-spectrum antibacterial drug, which has antibacterial effects on both Gram-positive and Gram-negative bacteria. However, bacterial resistance to this type of drug is common at present. The number of resistant strains in Staphylococcus, gonococci, meningococci, and Enterobacteriaceae has increased. Sulfonamides are also active against the following microorganisms: Chlamydia trachomatis, Nocardia asteroides, Plasmodium falciparum, and Toxoplasma gondii. Sulfonamides are broad-spectrum antibacterial agents, similar in structure to para-aminobenzoic acid (PABA), and can compete with PABA for dihydrofolate synthase in bacteria, thereby preventing PABA from being used as a raw material to synthesize folic acid required by bacteria, reducing the amount of metabolically active tetrahydrofolate, which is an essential substance for bacteria to synthesize purine, thymidine, and deoxyribonucleic acid (DNA), thereby inhibiting the growth and reproduction of bacteria. The effects of sulfonamides can be antagonized by PABA and its derivatives (procaine, tetracaine). In addition, the presence of pus and tissue decomposition products also has an antagonistic effect because it provides substances necessary for bacterial growth.

This product contains sulfadiazine

This product is a suspension aqueous solution of fine particles, which will precipitate slightly after standing and become a uniform white suspension after shaking.

Used for infections such as hemolytic streptococci, meningococci, and pneumococci.

Oral administration, 10 ml at a time, twice a day. For the treatment of meningitis, 10 ml at a time, 4 times a day. Shake well before taking.

1. Allergic reactions are common and may manifest as drug eruptions. In severe cases, exudative erythema multiforme, exfoliative dermatitis, and bullous epidermolysis atrophic dermatitis may occur. There are also serum sickness-like reactions such as photosensitivity reactions, drug fever, joint and muscle pain, and fever. 2. Granulocytopenia or deficiency, thrombocytopenia, and aplastic anemia. Patients may experience sore throat, fever, pallor, and bleeding tendency. Therefore, when sulfonamides are used systemically, peripheral blood counts should be checked regularly, and the drug should be stopped in time if abnormalities are found. 3. Hemolytic anemia and hemoglobinuria. Patients who lack glucose-6-phosphate dehydrogenase are prone to this after using sulfonamides, and it is more common in newborns and children than in adults. 4. Hyperbilirubinemia and neonatal kernicterus. Because sulfonamides compete with bilirubin for protein binding sites, free bilirubin can be increased. Neonates have imperfect liver function and poor bilirubin handling, so they are more likely to develop hyperbilirubinemia and neonatal jaundice, and occasionally kernicterus. 5. Liver damage. Jaundice and hepatic dysfunction may occur, and in severe cases, acute liver necrosis may occur. Therefore, patients with liver dysfunction should avoid systemic use of sulfonamides. 6. Kidney damage. Crystalluria, hematuria, and tubular urine may occur. If this product is used for a long course of treatment and the dose is large, it is advisable to take sodium bicarbonate and drink plenty of water to prevent this adverse reaction. During treatment, urine routine should be checked at least 2-3 times a week. If crystalluria or hematuria is found, sodium bicarbonate should be given and a large amount of water should be drunk until the crystalluria and hematuria disappear. This product is prone to renal damage in patients with dehydration, shock, and the elderly, so it should be used with caution or avoided. This product should not be used in patients with renal dysfunction. Occasionally, patients have serious adverse reactions such as interstitial nephritis or renal tubular necrosis. 7. Nausea, vomiting, decreased appetite, diarrhea, headache, fatigue, etc., generally mild symptoms, do not affect continued medication. Occasionally, patients develop Clostridium difficile enteritis, and the drug should be discontinued at this time. 8. Occasionally, thyroid enlargement and hypofunction occur. 9. Central nervous system toxicity may occasionally occur, manifested as mental confusion, disorientation, hallucinations, euphoria or depression. If it occurs, the drug should be discontinued immediately. Although serious adverse reactions caused by sulfonamides are rare, they can be fatal, such as exudative erythema multiforme, exfoliative dermatitis, epidermolysis bullosa atrophic dermatitis, fulminant liver necrosis, agranulocytosis, aplastic anemia and other blood system abnormalities. Treatment should be closely observed, and the drug should be discontinued immediately when rash or other early signs of reaction appear. The above adverse reactions are more common in AIDS patients than in non-AIDS patients. The adverse reactions of sulfonamides involve various organs, which may be related to their metabolic process in the body and the patient's condition. The main form of metabolism of sulfonamides in the body is acetylation, but the toxicity of this type of drug is difficult to fully explain by acetylation. Sulfonamides are detoxified by cells under normal conditions, as these toxic substances can be cleared by glutathione and other substances. However, in some patients, such as those with immunodeficiency, the concentration of glutathione in the body is low, resulting in the accumulation of metabolites and toxic reactions. The acetylation process of sulfonamides in the human body can be fast or slow, and allergic reactions are more common in those with slow acetylation.

It is contraindicated for those who are allergic to sulfonamides, newborns and infants under two months old, and those with poor liver and kidney function.

Note for children: Not for use on newborns and infants under 2 months old.

Not yet clear.

Keep away from light, tightly closed, in a cool and dry place.

10%(g/ml)

24 months

Jiangsu Yabang Shengyuan Pharmaceutical Co., Ltd.

• Founded in:

  1979-11-07

• Address:

  No. 801, Xin'an Avenue, Binhai Pharmaceutical Industrial Park, Binhai County, Yancheng City

• Tax NO.:

  91320922703863611B

• Registered Funds:

  30 million yuan

• Website:

  Log in to view

• Email:

  Log in to view